144 related articles for article (PubMed ID: 1873794)
41. Antisense therapy.
Narayanan R; Akhtar S
Curr Opin Oncol; 1996 Nov; 8(6):509-15. PubMed ID: 8971471
[TBL] [Abstract][Full Text] [Related]
42. Antisense strategies for the control of aberrant gene expression.
Sczakiel G
J Hematother; 1994; 3(4):305-13. PubMed ID: 7735826
[TBL] [Abstract][Full Text] [Related]
43. [Detection of activated oncogenes by Southern blot analysis].
Urabe K; Sasazuki T
Nihon Rinsho; 1990 Aug; 48(8):187-92. PubMed ID: 2255080
[No Abstract] [Full Text] [Related]
44. Antisense regulation of oncogenes in human cancer.
Mukhopadhyay T; Roth JA
Crit Rev Oncog; 1996; 7(3-4):151-90. PubMed ID: 9258601
[TBL] [Abstract][Full Text] [Related]
45. Genetic instability and tumor development.
Nowell PC
Basic Life Sci; 1991; 57():221-8; discussion 228-31. PubMed ID: 1814285
[No Abstract] [Full Text] [Related]
46. Pharmacological inactivation of MYC for the treatment of cancer.
Felsher DW; Bradon N
Drug News Perspect; 2003; 16(6):370-4. PubMed ID: 12973448
[TBL] [Abstract][Full Text] [Related]
47. Control of oncogene expression by antisense nucleic acids.
Hélène C
Eur J Cancer; 1994; 30A(11):1721-6. PubMed ID: 7833151
[No Abstract] [Full Text] [Related]
48. Inhibition of cell cycle progression by antisense oligodeoxynucleotides.
Baserga R; Reiss K; Alder H; Pietrzkowski Z; Surmacz E
Ann N Y Acad Sci; 1992 Oct; 660():64-9. PubMed ID: 1340157
[TBL] [Abstract][Full Text] [Related]
49. RNA targeting in cancer cells.
Ceriani MC; Bevilacqua AM; Asnaghi L; Nicolin A
Suppl Tumori; 2002; 1(6):S22-4. PubMed ID: 12658898
[No Abstract] [Full Text] [Related]
50. Recent status of the antisense oligonucleotide approaches in oncology.
Ma L; Calvo F
Fundam Clin Pharmacol; 1996; 10(2):97-115. PubMed ID: 8737953
[TBL] [Abstract][Full Text] [Related]
51. Oligonucleotides as modulators of cancer gene expression.
Curcio LD; Bouffard DY; Scanlon KJ
Pharmacol Ther; 1997; 74(3):317-32. PubMed ID: 9352587
[TBL] [Abstract][Full Text] [Related]
52. Prospects for gene-directed therapy with antisense oligodeoxynucleotides.
Calabretta B; Skorski T; Szczylik C; Zon G
Cancer Treat Rev; 1993 Apr; 19(2):169-79. PubMed ID: 8481928
[No Abstract] [Full Text] [Related]
53. Gene therapy for cancer.
Kipps TJ
J Hematother; 1993; 2(3):367-72. PubMed ID: 7921998
[TBL] [Abstract][Full Text] [Related]
54. The role of proto-oncogenes in human cancer: implications for diagnosis and treatment.
Cline MJ
Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1297-301. PubMed ID: 3305447
[TBL] [Abstract][Full Text] [Related]
55. Better blocker: RNA interference dazzles research community.
Garber K
J Natl Cancer Inst; 2003 Apr; 95(7):500-2. PubMed ID: 12671010
[No Abstract] [Full Text] [Related]
56. Antisense agents in pharmacology.
Dolnick BJ
Biochem Pharmacol; 1990 Aug; 40(4):671-5. PubMed ID: 2201298
[No Abstract] [Full Text] [Related]
57. Antisense comes of age.
Flanagan WM
Cancer Metastasis Rev; 1998 Jun; 17(2):169-76. PubMed ID: 9770113
[TBL] [Abstract][Full Text] [Related]
58. Antisense inhibition of gene expression: a tool for studying the role of NMYC in the growth and differentiation of neuroectoderm-derived cells.
Neckers LM; Rosolen A; Whitesell L
J Immunother (1991); 1992 Oct; 12(3):162-6. PubMed ID: 1332744
[TBL] [Abstract][Full Text] [Related]
59. Antisense targeting of Mcl-1 has therapeutic potential in gastric cancer.
Zangemeister-Wittke U; Huwiler A
Cancer Biol Ther; 2006 Oct; 5(10):1355-6. PubMed ID: 17172809
[No Abstract] [Full Text] [Related]
60. Protooncogenes in the regulation of normal hematopoiesis. An antisense approach.
Calabretta B; Skorski T; Szczylik C; Caracciolo D; Valtieri M; Venturelli D
Ann N Y Acad Sci; 1992 Oct; 660():117-23. PubMed ID: 1285069
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
